MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
AbCellera Biologics Operating Expenses 2011-2026 | ABCL
Annual Operating Expenses AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 292 M | 344 M | 275 M | 269 M | 171 M | 77.1 M | 14 M | 7.99 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 344 M | 7.99 M | 181 M |
Quarterly Operating Expenses AbCellera Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.2 M | 66.7 M | 66.9 M | - | 100 M | 101 M | 64.8 M | - | 61.5 M | 61.4 M | 77.1 M | - | 63.6 M | 54.3 M | 91.6 M | - | 33.6 M | 34.7 M | 44.7 M | - | 11.1 M | 12.1 M | 6.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | 6.78 M | 57.6 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.22 | -2.32 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | -3.48 % | $ 4.47 M | China |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.5 | -2.63 % | $ 1.39 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
23.4 M | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Certara
CERT
|
237 M | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
598 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
709 M | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
16 M | $ 27.7 | 1.12 % | $ 361 M | USA |
 |
Genmab A/S
GMAB
|
67.9 M | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 26.04 | -3.07 % | $ 697 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Codexis
CDXS
|
31.5 M | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
218 M | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
9.58 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Immunic
IMUX
|
103 M | $ 1.1 | 3.3 % | $ 171 M | USA |
 |
Immunovant
IMVT
|
438 M | $ 26.99 | -2.74 % | $ 4.09 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Inhibrx
INBX
|
221 M | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
9.78 M | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
INmune Bio
INMB
|
29.9 M | $ 1.41 | 6.07 % | $ 25.4 M | USA |
 |
Insmed Incorporated
INSM
|
348 M | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
46 M | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Innate Pharma S.A.
IPHA
|
71.7 M | $ 1.63 | -1.21 % | $ 235 M |  France |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
543 M | $ 29.11 | -0.31 % | $ 1.69 B | USA |